Bed bugs quail after exposure to Merck drug; Congress eyes compounding as FDA reports violations;

@FiercePharma: Israeli legal scholars move to sue Teva for shrouding details on executive pay. More | Follow @FiercePharma

> Merck's ($MRK) Stromectol, a treatment for parasitic worms, might be useful in controlling bed bugs, a study found. Report

> Congressional hearings will focus on the business practices of New England Compounding Center and on whether regulators did enough to police them. Report | More

> Belgium-based Arseus has bought three companies that supply ingredients to compounding pharmacies and plans to buy more this year, anticipating growth in the field. Report

> Watson Pharmaceuticals ($WPI) won FDA approval for its version of Pfizer's ($PFE) blood pressure drug Revatio. Report

> Germany's Boehringer Ingelheim plans to focus on its branded drugs, rather than branded generics, and on consumer health products for expansion in India. Report

Biotech News

 @FierceBiotech: Trending on FierceBiotech.com: 10 Top Women in Biotech 2012. Special Report | Follow @FierceBiotech

 @JohnCFierce: Alnylam to pay $75M to settle legal squabble over Tekmira's RNAi delivery tech. Story | Follow @JohnCFierce

 @RyanMFierce: $GILD is looking smart today for buying 7977. Market cap appears to have jumped $6.8B yesterday on news of its 100% SVR with hep C slayer. | Follow @RyanMFierce

> Fast-growing Gilead Sciences blueprints expansion, new R&D hires. News

> Pearl lands $65M round to fuel PhIII COPD showdown with Novartis, GSK. Story

Medical Device News

 @FierceMedDev: Chinese device maker Dehaier Medical saw Q3 revenue dip. The reason: an expansion strategy has yet to fully take hold. More | Follow @FierceMedDev

 @MarkHFierce: PerkinElmer snatched up an infectious disease Dx company based in China. More | Follow @MarkHFierce

 @DamianFierce: Hologic took a dive in the last quarter but predicts its $3.8B Gen-Probe buy will brighten the future. Story | Follow @DamianFierce

> Epic Sciences nabs $13M for cancer diagnostics. News

> China's Dehaier Medical Systems' Q3 stagnates as seeds planted for expansion. Report

Biotech Research News

> Harvard's microchip, lined with living cells, mimics disease in preclinical drug test. Report

> Stem cells produce the next potential Alzheimer's treatment. Item

> Kancera credits new drug with slowing pancreatic cancer tumor growth. Article

> Anti-inflammatory drugs that minimize infection risk appear possible. News

> Scientists crack genetic code for rare childhood leukemia variation. Story

Pharma Manufacturing News

> Lundbeck manufacturing starts small in China. Report

> Orchid closing up shop in China. More

> EFCG demands EU inspections of foreign API makers. Article

> FDA confirms Novartis plant, renewing CEO's confidence. Story

> Pilot shows national track and trace 'not insurmountable'. Editor's Corner

And Finally... If heartburn drugs don't work, it might not be the right kind of heartburn. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.